Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
January 26, 2023 12:15 ET
|
Psycheceutical Bioscience, Inc.
MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for...
Trimera Health Offers Medical Marijuana to Treat Patients With PTSD
January 05, 2023 14:00 ET
|
Trimera Health
HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Trimera Health is offering psychiatric treatment for post-traumatic stress disorder (PTSD) patients using marijuana, or cannabis, and building an uplifting...
Odyssey Health, Inc. Provides a Year End Update on Company and Corporate Outlook for 2023
December 19, 2022 08:30 ET
|
Odyssey Health, Inc
Las Vegas, Nevada, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing life-enhancing medical products, today...
Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder
December 18, 2022 19:34 ET
|
Bionomics Ltd
BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary EndpointSubjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to...
Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer
December 15, 2022 18:35 ET
|
Bionomics Ltd
ADELAIDE, Australia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric...
Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
December 02, 2022 06:00 ET
|
Bionomics Ltd
ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development
November 23, 2022 08:30 ET
|
Odyssey Health, Inc
Las Vegas, Nevada, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States
November 21, 2022 18:13 ET
|
Bionomics Ltd
ADELAIDE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing novel,...
Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States
November 16, 2022 18:36 ET
|
Bionomics Ltd
ADELAIDE, Australia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing novel,...
Odyssey Health, Inc. Schedules Annual Meeting of Stockholders
November 15, 2022 08:00 ET
|
Odyssey Health, Inc
Las Vegas, Nevada, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on...